BTL Vanquish FDA Cleared for Circumferential Reduction of Abdomen Area

June 30, 2015

BTL Industries received FDA clearance of its BTL Vanquish device for circumferential reduction of the abdomen area. BTL Vanquish uses a panel array that emits selective RF energy with the largest spot size in the industry to treat the entire core in one application. Providing a clinically proven and safe treatment option without touching the patient’s skin, the breakthrough technology of BTL Vanquish surpasses earlier treatment options that require uncomfortable suction or labor-intensive application. The system’s patented technology creates a high-frequency energy field that targets the thermal effects into the fat layer while protecting surrounding skin tissue.
Read more on AestheticsWire.

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds
    • Medical Marketing Whiz Recognized With Healthcare Digital Marketing Excellence Award
    • Allergan Presents Early Data on Skin Quality Treatments for Patients Taking Weight-Loss Medications
    • ValueCap Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s